Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …

Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …

Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of
antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional …

Introduction: Human ATP-binding cassette (ABC) transporters act as translocators of
numerous substrates across extracellular and intracellular membranes, thereby contributing …

The development of orally active small molecule inhibitors of the epidermal growth factor
receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC) …

Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly
expanding area of personalized chemotherapy and oral applicability thereof. The number of …

Recent pharmacogenomic/pharmacogenetic (PGx) studies have disclosed important roles
for drug transporters in the human body. Changes in the functions of drug transporters due …

Objectives During anticoagulant therapy, major bleeding is one of the most severe adverse
effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and …